Matches in SemOpenAlex for { <https://semopenalex.org/work/W3110611197> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W3110611197 endingPage "S1243" @default.
- W3110611197 startingPage "S1242" @default.
- W3110611197 abstract "Over 90% of patients with breast cancer are diagnosed with early breast cancer (EBC). While many patients with HR+ disease will not recur or have distant relapse with standard therapies, up to 30% of patients whose cancer has high risk clinical and/or pathological features may experience distant relapse, many in the first 2 years. Novel treatment options are needed to prevent early recurrences and development of metastases for these patients. Abemaciclib is an oral, continuously dosed CDK4 & 6 inhibitor approved for use in HR+, HER2- advanced breast cancer (ABC). Efficacy and safety of abemaciclib in ABC supported phase III evaluation in the adjuvant setting. monarchE, an open-label, phase III study, included patients with HR+, HER2-, high risk EBC, who completed primary treatment. Patients with ≥4 positive nodes, or 1-3 nodes and at least one of the following: tumor size ≥5 cm, histologic grade 3, or central Ki-67 ≥20%, were eligible, and randomized (1:1) to abemaciclib (150 mg BID for 2 years) plus endocrine therapy (ET) or ET alone. A prespecified interim analysis was planned at ∼293 IDFS events. The primary endpoint was invasive disease-free survival (IDFS) per STEEP criteria. Secondary endpoints included distant relapse-free survival (DRFS), overall survival, and safety. 5,637 patients were randomized. With 323 IDFS events observed in the intent-to-treat population, positive efficacy required a 2-sided p-value <0.0264. Abemaciclib plus ET demonstrated a statistically significant improvement in IDFS versus ET alone (p=.0096, HR: 0.747, 95% CI: 0.598, 0.932), corresponding to a 25.3% reduction in the risk of an IDFS event. The 2-year IDFS rates were 92.2% vs 88.7%, respectively. A similar improvement was observed for DRFS (HR: 0.717, 95% CI: 0.559, 0.920) with 2-year DRFS rates of 93.6% and 90.3%, respectively. Consistent benefit was seen in all prespecified subgroups. The most frequent AEs were diarrhea, neutropenia and fatigue in the abemaciclib arm and arthralgia, hot flush and fatigue in the control arm. Safety was consistent with the known profile of abemaciclib. Abemaciclib when combined with ET is the first CDK4 & 6 inhibitor to demonstrate a statistically significant improvement in IDFS in patients with HR+, HER2-, high risk EB." @default.
- W3110611197 created "2020-12-07" @default.
- W3110611197 creator A5002068827 @default.
- W3110611197 creator A5003060935 @default.
- W3110611197 creator A5007579054 @default.
- W3110611197 creator A5012008169 @default.
- W3110611197 creator A5018564985 @default.
- W3110611197 creator A5025820810 @default.
- W3110611197 creator A5027231412 @default.
- W3110611197 creator A5034632931 @default.
- W3110611197 creator A5034863656 @default.
- W3110611197 creator A5036907815 @default.
- W3110611197 creator A5040919295 @default.
- W3110611197 creator A5044707802 @default.
- W3110611197 creator A5048774512 @default.
- W3110611197 creator A5058390099 @default.
- W3110611197 creator A5068367016 @default.
- W3110611197 creator A5071111968 @default.
- W3110611197 creator A5071553983 @default.
- W3110611197 creator A5073900195 @default.
- W3110611197 creator A5083601910 @default.
- W3110611197 creator A5091553792 @default.
- W3110611197 date "2020-11-01" @default.
- W3110611197 modified "2023-10-16" @default.
- W3110611197 title "2MO Abemaciclib in high risk early breast cancer" @default.
- W3110611197 doi "https://doi.org/10.1016/j.annonc.2020.10.023" @default.
- W3110611197 hasPublicationYear "2020" @default.
- W3110611197 type Work @default.
- W3110611197 sameAs 3110611197 @default.
- W3110611197 citedByCount "1" @default.
- W3110611197 countsByYear W31106111972021 @default.
- W3110611197 crossrefType "journal-article" @default.
- W3110611197 hasAuthorship W3110611197A5002068827 @default.
- W3110611197 hasAuthorship W3110611197A5003060935 @default.
- W3110611197 hasAuthorship W3110611197A5007579054 @default.
- W3110611197 hasAuthorship W3110611197A5012008169 @default.
- W3110611197 hasAuthorship W3110611197A5018564985 @default.
- W3110611197 hasAuthorship W3110611197A5025820810 @default.
- W3110611197 hasAuthorship W3110611197A5027231412 @default.
- W3110611197 hasAuthorship W3110611197A5034632931 @default.
- W3110611197 hasAuthorship W3110611197A5034863656 @default.
- W3110611197 hasAuthorship W3110611197A5036907815 @default.
- W3110611197 hasAuthorship W3110611197A5040919295 @default.
- W3110611197 hasAuthorship W3110611197A5044707802 @default.
- W3110611197 hasAuthorship W3110611197A5048774512 @default.
- W3110611197 hasAuthorship W3110611197A5058390099 @default.
- W3110611197 hasAuthorship W3110611197A5068367016 @default.
- W3110611197 hasAuthorship W3110611197A5071111968 @default.
- W3110611197 hasAuthorship W3110611197A5071553983 @default.
- W3110611197 hasAuthorship W3110611197A5073900195 @default.
- W3110611197 hasAuthorship W3110611197A5083601910 @default.
- W3110611197 hasAuthorship W3110611197A5091553792 @default.
- W3110611197 hasBestOaLocation W31106111971 @default.
- W3110611197 hasConcept C121608353 @default.
- W3110611197 hasConcept C126322002 @default.
- W3110611197 hasConcept C143998085 @default.
- W3110611197 hasConcept C168563851 @default.
- W3110611197 hasConcept C203092338 @default.
- W3110611197 hasConcept C207103383 @default.
- W3110611197 hasConcept C2908647359 @default.
- W3110611197 hasConcept C44249647 @default.
- W3110611197 hasConcept C530470458 @default.
- W3110611197 hasConcept C61943457 @default.
- W3110611197 hasConcept C71924100 @default.
- W3110611197 hasConcept C99454951 @default.
- W3110611197 hasConceptScore W3110611197C121608353 @default.
- W3110611197 hasConceptScore W3110611197C126322002 @default.
- W3110611197 hasConceptScore W3110611197C143998085 @default.
- W3110611197 hasConceptScore W3110611197C168563851 @default.
- W3110611197 hasConceptScore W3110611197C203092338 @default.
- W3110611197 hasConceptScore W3110611197C207103383 @default.
- W3110611197 hasConceptScore W3110611197C2908647359 @default.
- W3110611197 hasConceptScore W3110611197C44249647 @default.
- W3110611197 hasConceptScore W3110611197C530470458 @default.
- W3110611197 hasConceptScore W3110611197C61943457 @default.
- W3110611197 hasConceptScore W3110611197C71924100 @default.
- W3110611197 hasConceptScore W3110611197C99454951 @default.
- W3110611197 hasLocation W31106111971 @default.
- W3110611197 hasOpenAccess W3110611197 @default.
- W3110611197 hasPrimaryLocation W31106111971 @default.
- W3110611197 hasRelatedWork W1964974194 @default.
- W3110611197 hasRelatedWork W2055804777 @default.
- W3110611197 hasRelatedWork W2057553101 @default.
- W3110611197 hasRelatedWork W2414402245 @default.
- W3110611197 hasRelatedWork W2567180275 @default.
- W3110611197 hasRelatedWork W2955230502 @default.
- W3110611197 hasRelatedWork W2969537103 @default.
- W3110611197 hasRelatedWork W377899687 @default.
- W3110611197 hasRelatedWork W4224323651 @default.
- W3110611197 hasRelatedWork W4322771458 @default.
- W3110611197 hasVolume "31" @default.
- W3110611197 isParatext "false" @default.
- W3110611197 isRetracted "false" @default.
- W3110611197 magId "3110611197" @default.
- W3110611197 workType "article" @default.